The BioNTech SE ADR BNTX rallied 1.59% to $117.64 Thursday, on what proved to be an all-around favorable trading session for ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

The BioNTech SE ADR BNTX rose 4.79% to $118.47 Tuesday, on what proved to be an all-around great trading session for the ...

Fintel reports that on September 24, 2024, Morgan Stanley upgraded their outlook for BioNTech SE - Depositary Receipt () ...

GSK's decision not to advance the vaccine into Phase III trials ends its ambition to bring the first HSV vaccine to market.

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Health Canada recently asked provinces and territories to get rid of their older COVID-19 vaccines to ensure the most current ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...

OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger. | ...

EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...